ArriVent BioPharma paid its 3 named executives $16.2M in total in FY2025 (Dec). CEO Zhengbin (Bing) Yao, Ph.D was paid $9.4M of that.
Pay$100 in the stock at the end of FY24 → $76
Pay of each named executive
Zhengbin (Bing) Yao, Ph.DChief Executive Officer and President
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Stuart Lutzker, M.D., Ph.DPresident, Research and Development
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Winston Kung, MBAChief Financial Officer and Treasurer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.